Immunovant's market cap is currently $2.69B. The company's EPS TTM is $-0.71; its P/E ratio is ―; Immunovant is scheduled to report earnings on August 11, 2025, and the estimated EPS forecast is $-0.71. See an overview of income statement, balance sheet, and cash flow financials.
